Skip to main content
SpringerLink
Log in
Book cover

Interferone pp 215–233Cite as

Zur Behandlung myeloproliferativer Syndrome mit Interferonen

  • Chapter

Zusammenfassung

Die erstmals 1951 synoptisch dargestellten chronischen myeloproliferativen Erkrankungen werden heute als Folge einer klonalen Transformation der hämatopoietischen Stammzellen verstanden [2, 15, 21]. Als charakteristisch gilt eine vermehrte Bildung und Akkumulation hämatopoietischer Zellen besonders in Knochenmark und Blut, aber auch in Leber und Milz (Tabelle 1). Vier Krankheitsentitäten mit unterschiedlicher Prognose können anhand klinischer, hämatologischer, histologischer und zytogenetischer Kriterien relativ sicher differenziert werden: die chronische myeloische Leukämie (CML), die essentielle Thrombozythämie (ET), die Polycythaemia vera (PCV) und die idiopathische Myelofibrose (IM) [29, 49]. Trotz der jeweils prädominanten Proliferation eines Zelltyps bestehen allerdings, zumindest in der Krankheitsfrühphase, fließende Übergänge zwischen den einzelnen Entitäten.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahegg-Werter MJBP, Raemaekers JMM, de Pauw BE, Haanen C (1990) Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia. Blut 60: 37–40

    Google Scholar 

  2. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L (1976) Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med 295: 913–916

    Google Scholar 

  3. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b as therapy for Ph′- positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 72: 642–647

    PubMed  CAS  Google Scholar 

  4. Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H (1989) A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 58: 275–278

    Article  PubMed  CAS  Google Scholar 

  5. Anger B, Haug U, Seidler R, Heimpel H (1989) Polycythemia vera. A clinical study of 141 patients. Blut 59: 493–500

    Article  PubMed  CAS  Google Scholar 

  6. Barosi G, Liberato LN, Costa A, Ascari E (1989) Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 58: 271–274

    Article  PubMed  CAS  Google Scholar 

  7. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, van Kessel AG, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277–280

    Google Scholar 

  8. Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, Boiron M (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58: 2440–2447

    Google Scholar 

  9. Bergsagel DE, Haas RH, Messner HA (1986) Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 13 (Suppl 2): 29–34

    PubMed  CAS  Google Scholar 

  10. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group Protocols. Semin Hematol 23: 132–143

    PubMed  CAS  Google Scholar 

  11. Broxmeyer HE, Lu L,Platzer E, Feit C, Juliano L, Rubin BY (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage ( CFU-GM) progenitor cells. J Immunol 131: 1300–1305

    Google Scholar 

  12. Broxmeyer HE, Cooper S, Rubin BY, Taylor MW (1985) The synergistic influence of human interferon gamma and interferon alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these to inhibition by interferons at low oxygen tension in vitro. J Immunol 135: 2502–2506

    PubMed  CAS  Google Scholar 

  13. Carlo-Stella C, Cazzola M, Ganser A, Bergamaschi G, Padrazzoli P, Hoelzer D, Ascari E (1988) Synergistic anti-proliferative effect of recombinant interferon-y with recombinant interferon-a on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). Blood 72: 1293–1299

    Google Scholar 

  14. Champlin RE, Golde DW (1985) Chronic myelogenous leukemia - recent advances. Blood 65: 1039–1047

    PubMed  CAS  Google Scholar 

  15. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372–375

    PubMed  CAS  Google Scholar 

  16. De Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp B, Groffen J, Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelogenous leukemia. Nature 300: 765–767

    Article  PubMed  Google Scholar 

  17. Denz H, Lechleitner M, Marth C, Daxenbichler G, Gastl G, Braunsteiner H (1985) Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematological malignancies. J Interferon Res 5: 147–157

    Article  PubMed  CAS  Google Scholar 

  18. Dölken G, Lange W, Siegert W, Finke J, Lohr GW (1989) Polymerase chain reaction for the detection of chimeric BCR-ABL mRNAs in patients with chronic myelogenous leukemia - detection of minimal residual disease after bone marrow transplantation. Mol Biother 1 ( Suppl ): Abstr. 79

    Google Scholar 

  19. Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 23: 144–155

    PubMed  CAS  Google Scholar 

  20. Espinosa E, De Castro R, Carnot J, Dorticos E, Estrada M, Gonzalez X, Hernandez P, Travieso J, Vega G, Vidal H, Ramirez V, Limonta M (1986) Treatment of chronic myelocytic leukemia with human leukocyte alpha interferon. Abstr. 2nd Cuban Sem Interferon Biotechnol, Havana

    Google Scholar 

  21. Fialkow PJ, Jacobson RJ, Papayannopoulou T (1977) Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer J Med 63: 125–130

    Google Scholar 

  22. Fleischmann WR, Fleischmann CM, Fiers W (1984) Potentiation of interferon action by mixtures of recombinant DNA-derived human interferons. Antiviral Res 4: 357–360

    Article  PubMed  CAS  Google Scholar 

  23. Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H (1989) Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Brit J Haematol 73: 350–356

    Google Scholar 

  24. Freund M, Fonatsch C, Blessmann B, Tischler J, Eisert R, von Wussow P, Exeriede G, Hiddemann W, Link H, Wilke H, Buhr Th, Poliwoda H (1989) Interferon alpha-2b (IFN alpha-2b) in CML. Experiences with two treatment regimens. Mol Biother 1 ( Suppl ): Abstr 78

    Google Scholar 

  25. Friche E, Hansen MM, Wieslander S (1988) Refractoriness to -interferon ( Intron A) in previously chemotherapy-treated patients with chronic myelocytic leukaemia. Eur J Haematol 40: 305–308

    Google Scholar 

  26. Gastaut JA (1988) Le chromosome Philadelphie disparaît-il après traitement par l’interferon? Presse Méd 17: 639–644

    PubMed  CAS  Google Scholar 

  27. Gastl G, Aulitzky Q, Tilg H, Huber H, Hausmaninger H, Seewann HL, Coser C, Prinoth P, Huber C (1987) Dose related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut 54: 251–252

    Article  PubMed  CAS  Google Scholar 

  28. Gastl (persönliche Mitteilung), 1989

    Google Scholar 

  29. Georgii A (1982) Klassifikation der chronischen myeloproliferativen Erkrankungen durch Histopathologic und Zytogenetik des Knochenmarkes. (Karger, Basel) Beitr Onkol 13: 166–188

    Google Scholar 

  30. Giles FJ, Singer CRJ, Gray AG, Yong KL, Brozovic M, Davies SC, Grant IR, Hoffbrand AV, Machin SJ, Mehta AB, Richards JDM, Thomas MJG, Venutas S, Goldstone AH (1988) Alpha-interferon therapy for essential thrombocythaemia. Lancet 2: 70–72

    Article  PubMed  CAS  Google Scholar 

  31. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz TH (1989) Long- term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1: 634–637

    Article  PubMed  CAS  Google Scholar 

  32. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldman H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202–207

    Article  PubMed  CAS  Google Scholar 

  33. Gonzales R, Robinson W, Adlakha A, Lamb R, Rovira D, Ferguson J, Saks S, Bunn P (1989) Efficacy and toxicity of gamma interferon in chronic myelogenous leukemia. Proc Am Soc clin Oncol 8: 209

    Google Scholar 

  34. Greenberg PL, Mosny SA (1977) Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res 37: 1794–1799

    PubMed  CAS  Google Scholar 

  35. Guilhot F, Tanzer J, Brizard A, Dreyfus B, Huret JL, Desmarest MC, Briaut S (1988) Traitement de la leucémie myeloide chronique par interferon alpha recombinant et hydroxyuree. La Presse Médicale 17: 1491

    Google Scholar 

  36. Hasselbalch H (1988) Interferon in myelofibrosis. Lancet 1: 355

    Article  PubMed  CAS  Google Scholar 

  37. Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queißer U, Vaupel H, Walther F, Hossfeld DK, Zimmermann R, Heiss F, Mende S, Tigges FJ, Kleeberg UR, Pralle H, Kayser W, Zimmermann R, Tichelli A, Faulhaber JD, Räth U, Schubert H, Bross K, Schlag R, Schmid L, Weißenfels I, Heinze B, Georgii A, Queißer W, Heimpel H (1988) Randomized study on the treatment of chronic myeloid leukemia ( CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 56: 87–91

    Article  PubMed  CAS  Google Scholar 

  38. Hehlmann R, Jahn M, Baumann B, Kopeke W (1988) Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 61: 2487–2496

    Article  PubMed  CAS  Google Scholar 

  39. Herrmann F, Lindemann A, Otto J, Mertelsmann R (1988) In vivo effects of interferon- gamma in chronic myelogenous leukemia. In: Huhn D, Hellriegel KP, Niederle N (Eds.): Chronic Myelocytic Leukemia and Interferon. Pathophysiological, Clinical and Therapeutical Aspects. Springer-Verlag Berlin Heidelberg New York London Paris Tokyo: 113–118

    Google Scholar 

  40. Howard OMZ, Talpaz M, Kartarjian HM, Wedrychowski A, Seong D, Turpin J, Gutterman J, Freireich E, Deisseroth A (1989) Clinical responsiveness to alpha-interferon correlates with interferon-induced changes in binding of nuclear proteins to regulatory regions of interferon-inducible genes in CML. Proc Am Soc Clin Oncol 8: 7

    Google Scholar 

  41. Kantarjian HM,Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B. Trujillo J, Freireich EJ (1985) Intensive combination polychemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3: 192–200

    Google Scholar 

  42. Kantarjian H, Talpaz M, Keating M, Walters R, Estey E, Andersson B, Beran M, Trujillo J, McCredie K, Freireich E (1986) Therapy of Philadelphia chromosome positive chronic myelogenous leukemia with initial intensive chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon (IFN-A). Blood 68 (Suppl 1), 224a

    Google Scholar 

  43. Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R (1985) The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140: 230–238

    Article  PubMed  CAS  Google Scholar 

  44. Kloke O, Becher R, Niederle N (1987) Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia. Blut 55: 453–458

    Article  PubMed  CAS  Google Scholar 

  45. Kloke O, Moritz T, Piadeck E, Nagel-Hiemke M, Niederle N (1989) Combined administration of IFN alfa and TNF alfa in patients with chronic myelogenous leukemia and secondary resistence to IFN. Mol Biother 1 ( Suppl ): Abstr. 104

    Google Scholar 

  46. Koeffler HP, Golde DW (1981) Chronic myelogenous leukemia - new concepts. N Engl J Med 304: 1201–1209

    Article  PubMed  CAS  Google Scholar 

  47. Kurzrock R, Talpaz M, Kantarijian H, Walters R, Saks S, Trujillo JM, Gutterman JU Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70: 943–947

    Google Scholar 

  48. Landaw SA (1986) Acute leukemia in polycythemia vera. Semin Hematol 23: 156–165

    PubMed  CAS  Google Scholar 

  49. Laszlo J (1975) Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 12: 409–432

    PubMed  CAS  Google Scholar 

  50. Lee M-S, Chang K-S, Freireich EJ, Kantarjian HM, Talpaz M, Trujillo JM, Stass SA (1988) Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 72: 893–897

    PubMed  CAS  Google Scholar 

  51. Lee M-S, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA (1989) Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood 73: 2165–2170

    PubMed  CAS  Google Scholar 

  52. Loeffler H, Schmitz N (1988) Allogeneic bone marrow transplantation for CML in Austria and West Germany. Blut 57: 221

    Google Scholar 

  53. Mahmoud HK, Schaefer UW, Schüning F, Beelen D, Becher R, Schmidt CG, Alberts W, Haralambie E, Linzenmeier G, Stollmann B, Grosse-Wilde H, Richter HJ, Hantschke D, Luboldt W (1985) Bone marrow transplantation for chronic granulocytic leukemia. Klin Wschr 63: 560–564

    Article  PubMed  CAS  Google Scholar 

  54. Manoharan A(1988) Annotation. Myelofibrosis: Prognostic factors and treatment. Brit. J. Haematol 69: 295–298

    Google Scholar 

  55. May D, Wandl UB, Niederle N (1989) Treatment of essential thrombocythaemia with interferon alpha-2b. Lancet 1: 96

    Article  PubMed  CAS  Google Scholar 

  56. McGlave P, Mamus S, Vilen B, Dewald G (1987) Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Hematol 15: 331–335

    PubMed  CAS  Google Scholar 

  57. Mills KI, MacKenzie ED, Birnie GD (1988) The site of the breakpoint within bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 72: 1237–1241

    PubMed  CAS  Google Scholar 

  58. Murphy S, Iland H, Rosenthal D, Laszlo J (1986) Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 23: 177–182

    Google Scholar 

  59. Neumann HA, Fauser AA (1982) Effect of interferon on pluripotent hemopoietic progenitors ( CFU-GEMM) derived from human bone marrow. Exp Hematol 10: 587–590

    Google Scholar 

  60. Niederle N, Kurschel E, Schmidt CG (1984) Biologischer Effekt von rekombinantem Leukozyten-alpha2-Interferon bei metastasierten kolorektalen Karzinomen. Dtsch med Wschr 109, 779–782

    Article  PubMed  CAS  Google Scholar 

  61. Niederle N, Kurschel E, Schütte J, Krischke W, Schmidt CG, Gerlis L, Gutzwiller E (1985) Phase I study of recombinant human interferon gamma (rlFN-y) in patients with advanced cancer. In: Kirchner H, Schellekens H (Eds.): The Biology of the Interferon System 1984. Amsterdam Elsevier, 509–515

    Google Scholar 

  62. Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG (1987) Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 14 (Suppl 2): 29–35

    PubMed  CAS  Google Scholar 

  63. Niederle N, Kloke O, Osieka R, May D, Wandl UB, Becher R, Opalka B, Schmidt CG (1988) Treatment of chronic and acute phase chronic myelogenous leukemia with interferon alpha-2b and interferon gamma. In: Huhn D, Hellriegel KP, Niederle N (Eds.): Chronic Myelocytic Leukemia and Interferon. Pathophysiological, Clinical and Therapeutical Aspects. Springer-Verlag, Berlin - Heidelberg - New York - London - Paris - Tokyo: 119–128

    Google Scholar 

  64. Niederle N, Wandl U, Kloke O, Nagel-Hiemke M, May D, Becher R, Overkamp F, Opalka B, Schmidt CG (1989) Efficacy of interferon alfa (IFN alfa-2b) and I FN gamma in chronic myelogenous leukemia ( CML ). Proc Am Soc Clin Oncol 8: 185

    Google Scholar 

  65. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497

    Google Scholar 

  66. Opalka B, Kloke O, Bartram CR, Beer U, Janssen JWG, Wandl UB, Niederle N (1989) Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia. Lancet 1: 1334

    Article  PubMed  CAS  Google Scholar 

  67. Opalka B, Beer U, Niederle N, Wandl U, Kloke O, Schmidt CG (1989) Breakpoints outside the major bcr region (mbcr) do not define a clinically destinct group of CML patients. Proc Am Ass Cancer Res 30: 227

    Google Scholar 

  68. Opalka B, Wandl U, Kloke O, Beer U, Kirch HC, Niederle N (1989) Localization of the breakpoint in the mbcr does not correlate with the clinical course in CML patients undergoing interferon therapy. Blood 74: 367a

    Google Scholar 

  69. Ozer H, Mick R, Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD for CALGB (1989) Subcutaneous a-interferon produces clinical and cytogenetic remission in untreated chronic phase Philadelphia chromosome positive chronic myelogenous leukemia. Mol Biother 1 ( Suppl ): Abstr. 76

    Google Scholar 

  70. Parmeggiani L, Ferrant A, Rodhain J, Michaux JL, Sokal G (1987) Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39: 228–232

    Article  PubMed  CAS  Google Scholar 

  71. Przepiorka D (1988) Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. Cancer Genet Cytogenet 36: 117–122

    Article  PubMed  CAS  Google Scholar 

  72. Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU (1986) In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha- interferon: Correlation with receptor binding and induction of 2,5-oligoadenylate synthetase. Cancer Res 46: 4848–4852

    PubMed  CAS  Google Scholar 

  73. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.) 243: 290–293

    Article  CAS  Google Scholar 

  74. Russo D, Fanin R, Zuffa E, Gallizia C, Michieli MG, Damiani D, Testoni N, Pecile V, Visani G, Colombini R, Tosi P, Baccarani M, Tura S (1989) Treatment of Ph + chronic myeloid leukemia by gamma interferon. Blut 59: 15–20

    Article  PubMed  CAS  Google Scholar 

  75. Sandberg A (1980) Chromosomes and causation of human cancer and leukemia XL. The Ph’ and other translocations in CML. Cancer 46: 2221–2226

    Article  PubMed  CAS  Google Scholar 

  76. Seewann HL, Gastl G, Lang A, Abbrederis K, Thaler J, Flener R, Huber CH (1988) Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56: 161–163

    Article  PubMed  CAS  Google Scholar 

  77. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M (1988) Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 72: 485–490

    PubMed  CAS  Google Scholar 

  78. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond.) 315: 550–554

    Article  CAS  Google Scholar 

  79. Silver RT, Gale RP (1986) Chronic myeloid leukemia. Amer J Med 80: 1137–1147

    Article  PubMed  CAS  Google Scholar 

  80. Silver RT (1988) Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 2: 403

    Article  PubMed  CAS  Google Scholar 

  81. Stam K, Heisterkamp N, Grosveld G, De Klein A, Verma RS, Coleman M, Dosik H, Groffen J (1985) Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 313: 1429–1433

    Article  PubMed  CAS  Google Scholar 

  82. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leukocyte interferon- induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692

    PubMed  CAS  Google Scholar 

  83. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069

    Article  CAS  Google Scholar 

  84. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288

    PubMed  CAS  Google Scholar 

  85. Talpaz M, Kurzrock R, Kantarjian H, Keating M, Evans L, Saks S, Gutterman J (1988) Therapy of Philadelphia positive chronic myelogenous leukemia with recombinant alpha A interferon and recombinant gamma interferon. Blood 72: 229a

    Google Scholar 

  86. Talpaz M, Kurzrock R, Kantarjian H, O’Brien S, Gutterman JU (1989) Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 86: 554–558

    Article  PubMed  CAS  Google Scholar 

  87. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163

    PubMed  CAS  Google Scholar 

  88. Tichelli A, Gratwohl A, Berger C, Lori A, Würsch A, Dieterle A, Thomssen C, Nissen C, Holdener E, Speck B (1989) Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a. Blut 58: 15–19

    Article  PubMed  CAS  Google Scholar 

  89. Toretsky JA, Shahidi NT, Finlay JL (1986) Effects of recombinant human interferon gamma on hematopoietic progenitor cell growth. Exp Hematol 14: 182–186

    PubMed  CAS  Google Scholar 

  90. Velu T, Delwiche F, Gangji D, Monsieur R, Flament J, Stryckmans P, Wybran J, Bellens R (1985) Therapeutic effect of human recombinant interferon-alpha-2c in essential thrombocythaemia. Oncology 42 (Suppl. 1): 10–14

    Article  PubMed  Google Scholar 

  91. Visani G, Russo D, Damiani D, Rizzi S, Motta MR, Lemoli RM, Poluzzi C, Fanin R, Zuffa E, Tosi P, Baccarani M, Tura S. (1988) Sensitivity of Ph 1 + CFU-GM to human recombinant interferon a and y in combination. Blut 57: 41–44

    Article  PubMed  CAS  Google Scholar 

  92. Wandl UB, Kloke O, Opalka B, Niederle N (1988) Suppressive effect of interferon alpha-2b on hematopoietic progenitor cells in patients with chronic myelogenous leukemia. In: Huhn D, Hellriegel KP, Niederle N (eds) Chronic Myelocytic Leukemia and Interferon. Pathophysiological, Clinical and Therapeutical Aspects. Springer, Berlin - Heidelberg - New York - London - Paris - Tokyo:84–90

    Google Scholar 

  93. Wickramasinghe SN, Peart S, Gill DS (1987) Alpha-interferon in primary idiopathic myelofibrosis. Lancet 2: 1524–1525

    Article  PubMed  CAS  Google Scholar 

  94. Williams CKO, Svet-Moldavskaya I, Vilcek J, Ohnuma T, Holland JF (1981) Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 38: 356–360

    Article  PubMed  CAS  Google Scholar 

  95. Wussow P von, Hartmann F, Freund M, Poliwoda H, Deicher H (1988) Leucocyte- derived interferon-alpha in patients with antibodies to recombinant IFN-a2b. Lancet 1: 882–883

    Article  Google Scholar 

  96. Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M (1987) Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69: 961–963

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. N. Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Med. Klinik III - Onkologie und Hämatologie, Städtisches Krankenhaus, Dhünnberg 60, D-5090, Leverkusen, Deutschland

    Norbert Niederle

  2. Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    Peter von Wussow

  3. Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    Peter von Wussow

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Niederle, N. (1990). Zur Behandlung myeloproliferativer Syndrome mit Interferonen. In: Niederle, N., von Wussow, P. (eds) Interferone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93383-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93383-7_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-93384-4

  • Online ISBN: 978-3-642-93383-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation